Somatostatin Receptors in Bronchopulmonary Neuroendocrine Neoplasms: New Diagnostic, Prognostic, and Therapeutic Markers

Bertino, 2009, Pulmonary neuroendocrine/carcinoid tumors: a review article, Cancer, 115, 4434, 10.1002/cncr.24498

Gustafsson, 2008, Bronchopulmonary neuroendocrine tumors, Cancer, 113, 5, 10.1002/cncr.23542

Hörsch, 2012, [Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system], Pneumologie, 66, 44, 10.1055/s-0031-1291478

Klimstra, 2013, Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging, Semin Oncol, 40, 23, 10.1053/j.seminoncol.2012.11.001

Siddiqui, 2010, Pulmonary neuroendocrine neoplasms: a review of clinicopathologic and cytologic features, Diagn Cytopathol, 38, 607, 10.1002/dc.21244

Swarts, 2012, Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities, Biochim Biophys Acta, 1826, 255

Pavel, 2013, Systemic therapeutic options for carcinoid, Semin Oncol, 40, 84, 10.1053/j.seminoncol.2012.11.003

Righi, 2010, Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases, Ann Oncol, 21, 548, 10.1093/annonc/mdp334

Zheng, 2013, Utility of the quantitative Ki-67 proliferation index and CD56 together in the cytologic diagnosis of small cell lung carcinoma and other lung neuroendocrine tumors, Acta Cytol, 57, 281, 10.1159/000346394

Fischer, 2008, Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1, J Clin Endocrinol Metab, 93, 4519, 10.1210/jc.2008-1063

Baum, 2012, THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy—the Bad Berka Experience, Theranostics, 2, 437, 10.7150/thno.3645

Baum, 2012, Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms, Semin Nucl Med, 42, 190, 10.1053/j.semnuclmed.2012.01.002

Campana, 2013, Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence, Eur J Nucl Med Mol Imaging, 40, 1197, 10.1007/s00259-013-2402-2

Kaemmerer, 2012, Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors, Int J Clin Exp Pathol, 5, 187

Kowalski, 2003, Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors, Mol Imaging Biol, 5, 42, 10.1016/S1536-1632(03)00038-6

Papotti, 2002, Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis, Virchows Archiv, 440, 461, 10.1007/s00428-002-0609-x

Reubi, 2013, Illuminating somatostatin analog action at neuroendocrine tumor receptors, Trends Pharmacol Sci, 34, 676, 10.1016/j.tips.2013.10.001

Toumpanakis, 2013, Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors, Semin Oncol, 40, 56, 10.1053/j.seminoncol.2012.11.006

Baum, 2008, Receptor PET/CT imaging of neuroendocrine tumors, Recent Results Cancer Res, 170, 225, 10.1007/978-3-540-31203-1_18

Ono, 2007, Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727, Anticancer Res, 27, 2231

Kaemmerer, 2011, Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT, Cancer Imaging, 11, 179, 10.1102/1470-7330.2011.0035

Ambrosini, 2009, 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid, Nucl Med Commun, 30, 281, 10.1097/MNM.0b013e32832999c1

Lupp, 2013, Reevaluation of sst1 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7, Regul Pept, 183, 1, 10.1016/j.regpep.2013.02.001

Lupp, 2012, Reassessment of sst3 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-5, Neuroendocrinology, 96, 301, 10.1159/000337659

Lupp, 2011, Reassessment of sst(5) somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4, Neuroendocrinology, 94, 255, 10.1159/000329876

Remmele, 1987, [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue], Der Pathologe, 8, 138

McCarty, 1985, Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies, Arch Pathol Lab Med, 109, 716

Pentheroudakis, 2011, Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study, Breast Cancer Res Treat, 127, 179, 10.1007/s10549-011-1427-0

Kimura, 1999, Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors, Clin Cancer Res, 5, 3483

Mizutani, 2012, Expression of somatostatin receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using real-time RT-PCR method and immunohistochemistry, Acta Histochem Cytochem, 45, 167, 10.1267/ahc.12006

Papotti, 2001, Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy, Virchows Archiv, 439, 787, 10.1007/s004280100494

Reubi, 1998, Immunohistochemical localization of somatostatin receptors sst2A in human tumors, Am J Pathol, 153, 233, 10.1016/S0002-9440(10)65564-2

Reubi, 2000, Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location, J Clin Endocrinol Metab, 85, 3882

Papotti, 2000, Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung, Diagn Mol Pathol, 9, 47, 10.1097/00019606-200003000-00008

Tsuta, 2012, Differential expression of somatostatin receptors 1–5 in neuroendocrine carcinoma of the lung, Pathol Res Pract, 208, 470, 10.1016/j.prp.2012.05.014

Zatelli, 2005, Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid, J Clin Endocrinol Metab, 90, 2104, 10.1210/jc.2004-2156

Pelosi, 2006, Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy, Q J Nucl Med Mol Imaging, 50, 272

Schmid, 2012, Monoclonal antibodies against the human somatostatin receptor subtypes 1–5: development and immunohistochemical application in neuroendocrine tumors, Neuroendocrinology, 95, 232, 10.1159/000330616

Phan, 2010, NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus), Pancreas, 39, 784, 10.1097/MPA.0b013e3181ec1380

Zheng, 2012, A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors, Mol Pharm, 9, 1175, 10.1021/mp200464x

Pelosi, 2014, Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors, Endocr Pathol, 25, 151, 10.1007/s12022-014-9320-0

Pelosi, 2014, Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice, J Thorac Oncol, 9, 273, 10.1097/JTO.0000000000000092

Volante, 2008, Somatostatin, cortistatin and their receptors in tumours, Mol Cell Endocrinol, 286, 219, 10.1016/j.mce.2007.12.002

Zarogoulidis, 2012, Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients, Lung Cancer, 76, 84, 10.1016/j.lungcan.2011.09.014

van Hoek, 2009, Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies, J Clin Endocrinol Metab, 94, 428, 10.1210/jc.2008-1712

Rocheville, 2000, Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers, J Biol Chem, 275, 7862, 10.1074/jbc.275.11.7862

Kaemmerer, 2013, Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors, Int J Clin Exp Pathol, 6, 49

Kulaksiz, 2002, Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies, Gut, 50, 52, 10.1136/gut.50.1.52

Antunes, 2007, Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?, Eur J Nucl Med Mol Imaging, 34, 982, 10.1007/s00259-006-0317-x

Cukier, 2009, Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease, Clin Endocrinol (Oxf), 71, 305, 10.1111/j.1365-2265.2008.03486.x

Fedele, 2007, SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas, Clin Cancer Res, 13, 2738, 10.1158/1078-0432.CCR-06-2505

Schmid, 2005, Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats, J Endocrinol Invest, 28, 28

Bruns, 2002, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile, Eur J Endocrinol, 146, 707, 10.1530/eje.0.1460707

Rinke, 2009, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group, J Clin Oncol, 27, 4656, 10.1200/JCO.2009.22.8510